Endurance of erythrocyte series in chemotherapy

Săftescu,Sorin; Popovici,Dorel; Oprean,Cristina; Negru,Alina; Croitoru,Adina; Zemba,Mihail; Yasar,Ionela; Preda,Maria; Negru,Șerban

doi:10.3892/etm.2020.9344

Endurance of erythrocyte series in chemotherapy

Authors:
- Sorin Săftescu
- Dorel Popovici
- Cristina Oprean
- Alina Negru
- Adina Croitoru
- Mihail Zemba
- Ionela Yasar
- Maria Preda
- Șerban Negru
View Affiliations

Affiliations: Department of Oncology, ‘Victor Babeș’ University of Medicine and Pharmacy, 300041 Timisoara, Romania, Department of Cardiology, ‘Victor Babeș’ University of Medicine and Pharmacy, 300041 Timisoara, Romania, Department of Medical Oncology, Fundeni Clinical Institute, 022328 Bucharest, Romania, Department of Ophthalmology, ‘Carol Davila’ University of Medicine and Pharmacy, 050474 Bucharest, Romania, Department of Ophthalmology, ‘Victor Babeș’ University of Medicine and Pharmacy, 300041 Timisoara, Romania
Published online on: October 15, 2020 https://doi.org/10.3892/etm.2020.9344
Article Number: 214
Copyright: © Săftescu et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Hematopoietic bone marrow toxicity is most often the limiting factor for chemotherapy doses. Increasing the intensity of chemotherapy doses (higher doses or more frequent administration) would improve antitumor effects, but the hematological toxicity does not allow these dose increases. This study evaluated the impact of chemotherapies on the parameters belonging to the red blood cell series in the hemogram and aimed to identify some particular evolution profiles. We selected 855 evaluations performed before the administration of chemotherapy belonging to the treatments initiated during the period December 2018‑February 2020, containing 5‑fluorouracil, cisplatin, docetaxel, epirubicin or pemetrexed. The data of the 644 evaluations related to the cycles 1‑4 of chemotherapy were subject to this processing. The average relative loss of hemoglobin is ‑11% after the first three cycles of treatment, with statistically significant differences in hemoglobin levels in favor of men. There are risk factors associated with higher average losses, such as age <50 years or >65 years (statistically significant), body mass index (BMI) >25, cisplatin treatment (insufficient number of cases to reach statistical significance).

View Figures

View References

1	Eaves CJ and Eaves AC: Anatomy and physiology of hematopoiesis. In: Childhood Leukemias. 2nd edition. Pui CH (ed). Cambridge University Press, Cambridge, pp69-105, 2006.
2	Goodman SR, Kurdia A, Ammann L, Kakhniashvili D and Daescu O: The human red blood cell proteome and interactome. Exp Biol Med (Maywood). 232:1391–1408. 2007.PubMed/NCBI View Article : Google Scholar
3	Koury MJ: Erythroferrone: A missing link in iron regulation. The Hematologist. American Society of Hematology 12, 2015.
4	Kautz L, Jung G, Valore EV, Rivella S, Nemeth E and Ganz T: Identification of erythroferrone as an erythroid regulator of iron metabolism. Nat Genet. 46:678–684. 2014.PubMed/NCBI View Article : Google Scholar
5	Wan J, Ristenpart WD and Stone HA: Dynamics of shear-induced ATP release from red blood cells. Proc Natl Acad Sci USA. 105:16432–16437. 2008.PubMed/NCBI View Article : Google Scholar
6	Diesen DL, Hess DT and Stamler JS: Hypoxic vasodilation by red blood cells: Evidence for an s-nitrosothiol-based signal. Circ Res. 103:545–553. 2008.PubMed/NCBI View Article : Google Scholar
7	Kleinbongard P, Schutz R, Rassaf T, Lauer T, Dejam A, Jax T, Kumara I, Gharini P, Kabanova S, Ozüyaman B, et al: Red blood cells express a functional endothelial nitric oxide synthase. Blood. 107:2943–2951. 2006.PubMed/NCBI View Article : Google Scholar
8	Bunn HF: Approach to the anaemias. In: Goldman-Cecil Medicine. Goldman L, Schafer AI (eds.) 25th edition. Philadelphia, PA: Elsevier Saunders, Chapter 158, 2016.
9	Chernecky CC and Berger BJ: Blood indices-blood. In: Laboratory Tests and Diagnostic Procedures. Chernecky CC and Berger BJ (eds). 6th edition. Elsevier, Philadelphia, PA, pp217-219, 2013.
10	Walker HK, Hall WD and Hurst JW (eds.): Clinical Methods: The History, Physical, and Laboratory Examinations. 3rd edition. Butterworths, Boston, 1990.
11	Evans TC and Jehle D: The red blood cell distribution width. J Emerg Med. 9 (Suppl 1):S71–S74. 1991.PubMed/NCBI View Article : Google Scholar
12	Rambach L, Bertaut A, Vincent J, Lorgis V, Ladoire S and Ghiringhelli F: Prognostic value of chemotherapy-induced haematological toxicity in metastatic colorectal cancer patients. World J Gastroenterol. 20:1565–1573. 2014.PubMed/NCBI View Article : Google Scholar
13	Jung HA, Kim HJ, Maeng CH, Park SH, Lee J, Park JO, Park YS, Lim HY and Kang WK: Changes in the mean corpuscular volume after capecitabine treatment are associated with clinical response and survival in patients with advanced gastric cancer. Cancer Res Treat. 47:72–77. 2015.PubMed/NCBI View Article : Google Scholar
14	Papaldo P, Ferretti G, Di Cosimo S, Giannarelli D, Marolla P, Lopez M, Cortesi E, Antimi M, Terzoli E, Carlini P, et al: Does granulocyte colony-stimulating factor worsen anaemia in early breast cancer patients treated with epirubicin and cyclophosphamide? J Clin Oncol. 24:3048–3055. 2006.PubMed/NCBI View Article : Google Scholar
15	Groopman JE and Itri LM: Chemotherapy-induced anaemia in adults: Incidence and treatment. J Natl Cancer Inst. 91:1616–1634. 1999.PubMed/NCBI View Article : Google Scholar
16	Ludwig H and Fritz E: Anaemia in cancer patients. Semin Oncol. 25 (3 Suppl 7):S2–S6. 1998.
17	Stanca HT, Suvac E, Munteanu M, Jianu DC, Motoc AGM, Roşca GC and Boruga O: Giant cell arteritis with arteritic anterior ischemic optic neuropathy. Rom J Morphol Embryol. 58:281–285. 2017.PubMed/NCBI
18	Balica NC, Poenaru M, Doroş CI, Baderca F, Preda MA, Iovan VC, Stanca HT, Busuioc CJ, Oprişcan IC and Boruga O: The management of the oropharyngeal anterior wall cancer. Rom J Morphol Embryol. 59:113–119. 2018.PubMed/NCBI
19	Pirker R, Pirolli M, Quigley J, Hulnick S, Legg J, Collins H and Vansteenkiste J: Hemoglobin decline in cancer patients receiving chemotherapy without an erythropoiesis-stimulating agent. Support Care Cancer. 21:987–992. 2013.PubMed/NCBI View Article : Google Scholar
20	Mancuso A, Migliorino M, De Santis S, Saponiero A and De Marinis F: Correlation between anemia and functional/cognitive capacity in elderly lung cancer patients treated with chemotherapy. Ann Oncol. 17:146–150. 2006.PubMed/NCBI View Article : Google Scholar
21	Peterson LL, Hurria A, Feng T, Mohile SG, Owusu C, Klepin HD, Gross CP, Lichtman SM, Gajra A, Glezerman I, et al: Association between renal function and chemotherapy-related toxicity in older adults with cancer. J Geriatr Oncol. 8:96–101. 2017.PubMed/NCBI View Article : Google Scholar